Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRX011 in Geographic Atrophy Secondary to AMD
NCT07029945Phase 2Recruiting
- Sponsor
- BioJiva LLC
- Start
- Sep 2026
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in geographic atrophy (GA) comparing BRX011 with Placebo (2 arms). Primary endpoint: Annual rate of change in the square root of GA area at 96 weeks. Started Sep 2026; status: recruiting.
02
Drugs
BRX011
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT07029945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07029945.